Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558470 | 0.92 | NCF1 (0.39) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL4544646 | 0.86 | NCF1 (0.50) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL245769 | 0.84 | NCF1 (0.56) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL11164665 | 0.84 | NCF1 (0.56) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL11157613 | 0.81 | NCF1 (0.54) | NCF1ACHEGNAO1GNAI3GNAI1 | |
| SCHEMBL24193655 | 0.81 | CYP1A2 (0.40) | ALDH1A1SIGMAR1CYP1A2 | |
| SCHEMBL19959026 | 0.81 | ALDH1A1 (0.35) | GNAO1ALDH1A1SLC18A3CYP1A2 | |
| SCHEMBL25707220 | 0.80 | GNAO1 (0.49) | GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL24673857 | 0.79 | HRH3 (0.41) | GNAO1HRH3ALDH1A1CYP1A2 | |
| SCHEMBL25096216 | 0.79 | NCF1 (0.43) | NCF1ACHEGNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NCF1 2538/4885ACHE 3684/4885GNAO1 110/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NCF1 2471/4885ACHE 4285/4885GNAO1 103/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | NCF1 2731/4885ACHE 3827/4885GNAO1 1975/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | NCF1 2471/4885ACHE 4285/4885GNAO1 103/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | NCF1 947/4885ACHE 4882/4885GNAO1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.